Logotype for Evotec SE

Evotec (EVT) investor relations material

Evotec Q3 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Evotec SE
Q3 2025 earnings summary5 Nov, 2025

Executive summary

  • Group revenues for the first nine months of 2025 were €535.1 million, down 7% year-over-year, mainly due to a 12% decline in D&PD, while JEB grew 11% and outperformed expectations.

  • A landmark transaction with Sandoz was signed, including the sale of the Toulouse site and a technology license, with upfront and milestone payments totaling over $650 million and future royalties on up to 10 biosimilars.

  • Strategic partnerships advanced, with up to four molecules expected to enter phase II clinical studies in 2026 and over 100 assets in the pipeline.

  • The company is transitioning to a higher-margin, asset-light business model, focusing on technology leadership and IP licensing.

  • Net loss for the period improved to €(118.1)m from €(155.2)m in the prior year, driven by lower reorganization expenses and cost base.

Financial highlights

  • Group revenues: €535.1m (down 7% year-over-year); D&PD revenues: €391.9m (down 12%); JEB revenues: €143.2m (up 11%).

  • Gross margin declined to 6.7% from 11.9% year-over-year, mainly due to D&PD underperformance and JEB ramp-up costs.

  • Adjusted Group EBITDA was negative €16.9m, with D&PD at €(18.8)m and JEB at €1.9m.

  • Free cash flow for 9M 2025 was €-139.9m, but is expected to turn positive by year-end due to milestone payments and asset sales.

  • Cash and cash equivalents: €174.0m as of 30 September 2025, down from €306.4m at year-end 2024.

Outlook and guidance

  • 2025 revenue guidance confirmed at €760–800m, with adjusted EBITDA expected between €30–50m.

  • 2028 outlook targets 8–12% revenue CAGR and adjusted EBITDA margin above 20%.

  • Cost reduction initiatives are ahead of plan, with over €60m targeted for 2025 and further productivity measures planned.

  • Stable development expected, driven by JEB, with D&PD navigating a challenging market.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Evotec earnings date

Logotype for Evotec SE
Q4 202520 Apr, 2026
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Evotec earnings date

Logotype for Evotec SE
Q4 202520 Apr, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Evotec SE is a biotechnology company specializing in drug discovery and development services. The company collaborates with pharmaceutical and biotech firms, academic institutions, and research organizations to identify and develop therapeutic candidates across various disease areas, including neurology, oncology, and metabolic disorders. The company is headquartered in Hamburg, Germany, and its shares are listed on the FSE (Frankfurt Stock Exchange).

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage